Growth Capital • Life Science

Meiji Invests In Lyric Bio

On December 4, 2025, Meiji invested in life science company Lyric Bio

Investment Context

This is Meiji’s 2nd transaction in the Life Science sector.
This is Meiji’s 1st transaction in the United States.
This is Meiji’s 1st transaction in California.

Explore All 401 Growth Capital Life Science Deals - Search the Database Free

Investment Summary
Date	December 4, 2025
Target	Lyric Bio
Sector	Life Science
Investor(s)	Meiji
Deal Type	Growth Capital

Target Company

Lyric Bio

San Francisco, California, United States

Lyric Bio manufactures donor-derived and protein-based therapeutics, with an initial focus on immunoglobulin production. By leveraging proprietary tissue engineering technologies, it aims to end chronic shortages, reduce costs, and improve global drug access for life-saving medicines. Lyric Bio is based in San Francisco, California.

Explore More Deals

Browse All 215,262 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Investor Overview 1

Investor

Meiji

Tokyo , Japan

Category	Company
Founded	1946
Sector	Life Science

DESCRIPTION

Meiji is providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs, to meet various medical needs. Meiji was founded in 1946 and is based in Tokyo, Japan.

Deal Context for Investor	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Growth Capital	1 of 1
State: California	1 of 1
Country: United States	1 of 1
Year: 2025	1 of 1

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2024-11-14	ARCALIS Fukushima , Japan ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc. and Arcturus Therapeutics, Inc. ARCALIS was formed in 2021 and is based in Fukushima, Japan.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2024-11-14

ARCALIS

Fukushima , Japan

ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc. and Arcturus Therapeutics, Inc. ARCALIS was formed in 2021 and is based in Fukushima, Japan.

Buy

Explore Related M&A Activity

Life Science M&A - Growth Capital M&A Deals - California M&A - United States M&A - 2025 M&A